Prediction: AbbVie Will End The Year at This Price

Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts

Public Citizen maintained a CMS policy change “will cost the government more money and compromise patient access."

Prediction: AbbVie Will End The Year at This Price

AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about whether the rally has room left to run.